KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Net Cash Flow (2016 - 2025)

Acadia Pharmaceuticals (ACAD) has 16 years of Net Cash Flow data on record, last reported at -$81.9 million in Q4 2025.

  • For Q4 2025, Net Cash Flow fell 149.81% year-over-year to -$81.9 million; the TTM value through Dec 2025 reached -$142.8 million, down 206.58%, while the annual FY2025 figure was -$142.8 million, 206.58% down from the prior year.
  • Net Cash Flow reached -$81.9 million in Q4 2025 per ACAD's latest filing, down from $4.4 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $176.1 million in Q1 2023 and bottomed at -$180.6 million in Q2 2023.
  • Average Net Cash Flow over 5 years is -$7.3 million, with a median of -$15.5 million recorded in 2023.
  • Peak YoY movement for Net Cash Flow: skyrocketed 366.79% in 2022, then tumbled 733.51% in 2025.
  • A 5-year view of Net Cash Flow shows it stood at $52.8 million in 2021, then tumbled by 175.74% to -$40.0 million in 2022, then surged by 326.26% to $90.5 million in 2023, then soared by 81.82% to $164.5 million in 2024, then tumbled by 149.81% to -$81.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Cash Flow were -$81.9 million in Q4 2025, $4.4 million in Q3 2025, and $36.6 million in Q2 2025.